EU gives nod to Lilly, Novartis drugs; Lundbeck offers up Lexapro alternative;

 @FiercePharma: Philly judge lets J&J CEO Alex Gorsky off the hook; he can't be compelled to testify in Risperdal case. More | Follow @FiercePharma

> An advisory committee in the European Union is recommending approval of Eli Lilly's ($LLY) Cialis 5 mg for daily use to treat signs and symptoms of benign prostatic hyperplasia (BPH). Release

> EU regulators also on Friday gave recommendations to two Novartis ($NVS) drugs, Galvus and Eucreas, to be used in combo with other treatments for Type 2 diabetes. Story 

> Seattle is being hard hit by Dendreon's decision to cut 600 employees, with 145 of those coming from the Northwest city. Story 

> Thermo Fisher Scientific is inaugurating a new molecular biology center of excellence in Vilnius, Lithuania, targeting the Eastern European market. Story 

> Sanofi ($SNY) has again partnered with the Global Alliance for TB Drug Development to look for new treatments. Item 

> ViroPharma is rolling out Plenadren in Europe for the treatment of adrenal insufficiency. Item 

> Danish drugmaker Lundbeck has filed an application with EU regulators for a new generation of antidepressant, vortioxetine, as it deals with the loss of patent on its popular antidepressant, Lexapro. Story

Medical Device News

 @FierceMedDev: Devicemaker NeuroMetrix has 6 months to get its Nasdaq stock price up to the minimum bid. Release | Follow @FierceMedDev

 @MarkHFierce: After months of bad defibrillator news, St. Jude hits something better: A CE mark for a neurostim migraine treatment. Story | Follow @MarkHFierce

 @DamianFierce: Medtronic is back in court, facing a suit alleging that its pain pump left a man paralyzed. News | Follow @DamianFierce

> Less than $1M later, Washington device startup eyes FDA submission. More

> Australia bets on medical device R&D with new fund. Article

Biotech News

 @FierceBiotech: In case you missed it yesterday, check out our 2012 Fierce 15 slideshow from BioPharm America 2012. Slideshow | Follow @FierceBiotech

 @JohnCFierce: Progenics in Tarrytown gets out the ax (again), cuts research, lops staffers. Release | Follow @JohnCFierce

 @RyanMFierce: New pharma-academic tie-up. Bristol-Myers Squibb tapped academics at Vanderbilt on Parkinson's drug research. More | Follow @RyanMFierce

> MorphoSys zeroes in on partner for blockbuster hopeful against arthritis. News

> Vivus: EU regulators expected to balk on obesity drug. Report

> Google VC group eyes biotech bets with $1B purse. Story

And Finally... Amgen ($AMGN) says the FDA has approved Prolia for treating bone mass loss in men with osteoporosis who are at high risk for breaking bones. Release

Suggested Articles

Stephen Hahn, an oncologist who served as the chief medical officer for the MD Anderson Cancer Center, has secured Senate confirmation as FDA head.

As BMS searches for bright spots in its Opdivo-chemo combo fail from June, it’s zeroing in on squamous lung cancer patients who seemed to benefit.

The FDA's ad watchdog served its most serious violation to Alkermes Wednesday—and it took the unusual step of announcing that violation to the world.